Japan Phase III Start Cements Roxadustat’s Lead
Astellas/FibroGen's oral candidate for anemia in chronic kidney disease has moved into Phase III in Japan on the basis of promising Phase II results, cementing the global development lead for the first-in-class product and taking it closer to a potentially big market.
You may also be interested in...
The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.